Shijun Hao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shijun Hao has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Colleen A. Nugent
Digestive Diseases and Nutrition Center, Women and Children's Hospital of Buffalo, Department of Pediatrics, The State University of New York at Buffalo, Buffalo, NY 14214, USA
1 shared publication- Haiyan Song
Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China
1 shared publication - Lili Yang
Institute of Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
1 shared publication - Peiyong Zheng
Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China
1 shared publication - Tao Liu
Institute of Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
1 shared publication - Weili Lin
School of Life Sciences and Technology, Tongji University, Shanghai 200092, China
1 shared publication
Latest Publications
- Open Access
- 31 December 2017
- Published by Wiley in International Journal of Genomics
- Vol. 2017, 1-12
LingguizhuganDecoction Protects against High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease by Alleviating Oxidative Stress and Activating Cholesterol Secretion
Background. Nonalcoholic fatty liver disease (NAFLD) has become a leading cause of liver transplantation.Lingguizhugandecoction (LGZG), a classical Chinese herbal formula, has beneficial effects on NAFLD animal models. Our study examined the impact of LGZG on hepatic global transcriptome of high-fat-diet-induced NAFLD rats.Methods. Three groups of Wistar rats were included: normal, NAFLD model, and LGZG-treated NAFLD groups. Four weeks for the treatment, liver tissues were harvested for RNA sequencing. Differentially expressed genes (DEGs) and enriched pathways were detected on hepatic global transcriptome profile. Real-time PCR validated the regulatory patterns of LGZG on NAFLD rats.Results. DEGs between the NAFLD model and normal groups indicated the elevated peroxisome proliferator-activated receptor (PPAR) and hedgehog signaling pathways in NAFLD rats. In bile secretion pathway, genes involved in cholesterol secretion were activated by LGZG treatment. Increased expression of antioxidantOSIGN1and decreased expression of genes (AHR,IRF2BP2, andRASGEF1B) that induce oxidative stress and inflammation were observed in NAFLD rats treated with LGZG. The regulatory patterns of LGZG treatment on these oxidative stress-related genes were confirmed by real-time PCR.Conclusion. Our study revealed a “two-hits-targeting” mechanism of LGZG in the treatment for NAFLD: alleviating oxidative stress and activating cholesterol secretion.
- 31 December 2017
- Published by Wiley in International Journal of Genomics
- Vol. 2017, 1-12
Open AccessLingguizhuganDecoction Protects against High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease by Alleviating Oxidative Stress and Activating Cholesterol Secretion
Background. Nonalcoholic fatty liver disease (NAFLD) has become a leading cause of liver transplantation.Lingguizhugandecoction (LGZG), a classical Chinese herbal formula, has beneficial effects on NAFLD animal models. Our study examined the impact of LGZG on hepatic global transcriptome of high-fat-diet-induced NAFLD rats.Methods. Three groups of Wistar rats were included: normal, NAFLD model, and LGZG-treated NAFLD groups. Four weeks for the treatment, liver tissues were harvested for RNA sequencing. Differentially expressed genes (DEGs) and enriched pathways were detected on hepatic global transcriptome profile. Real-time PCR validated the regulatory patterns of LGZG on NAFLD rats.Results. DEGs between the NAFLD model and normal groups indicated the elevated peroxisome proliferator-activated receptor (PPAR) and hedgehog signaling pathways in NAFLD rats. In bile secretion pathway, genes involved in cholesterol secretion were activated by LGZG treatment. Increased expression of antioxidantOSIGN1and decreased expression of genes (AHR,IRF2BP2, andRASGEF1B) that induce oxidative stress and inflammation were observed in NAFLD rats treated with LGZG. The regulatory patterns of LGZG treatment on these oxidative stress-related genes were confirmed by real-time PCR.Conclusion. Our study revealed a “two-hits-targeting” mechanism of LGZG in the treatment for NAFLD: alleviating oxidative stress and activating cholesterol secretion.